Induction of broadly neutralizing antibodies (bnAbs) capable of inhibiting infection with diverse variants of human immunodeficiency virus type 1 (HIV-1) is a key, as-yetunachieved goal of prophylactic HIV-1 vaccine strategies. However, some HIV- 
I N V I T E D R E V I E W
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showing any degree of vaccine efficacy. 8 A number of antibody-mediated functions against HIV-1 have been studied, including virus capture and phagocytosis, 9, 10 antibodydependent cell-mediated virus inhibition, 11, 12 antibody-dependent cell-mediated cytotoxicity (ADCC), 13, 14 chemokine secretion of monocytes stimulated by antibodies, 15 and virus neutralization.
HIV-1, 19, 20 while the role of other antibody-mediated functions in exerting immune pressure is unclear, primarily because antibodies that mediate ADCC and other activities often also neutralize. 21 Regardless, multiple studies have demonstrated that virus neutralization is a driver of both virus and antibody diversity, [22] [23] [24] [25] [26] although neutralization of autologous viruses does not always cause the extinction of susceptible virus populations in an infected individual. 25 Because of their ability to neutralize many different circulating strains of HIV-1, broadly neutralizing antibodies (bnAbs) are attractive targets for vaccine development. 27 Passive infusion studies in animals have shown that bnAbs can prevent infection by intravenous 28 and mucosal [28] [29] [30] [31] [32] [33] challenge, suggesting that a vaccine that elicits robust and durable levels of bnAbs could be protective. Vaccine development strategies that leverage our understanding of antibody-virus coevolution 34 and that use knowledge of antibody-antigen structure relationships 27 are currently being tested in animal models 35, 36 and human studies are planned. However, to date, no vaccine has reliably elicited bnAbs, and one possibility is that in addition to optimizing antigen structure, it may be necessary to recreate the immunological environment in which bnAbs develop. Understanding the conditions in which bnAbs have developed is a critical first step toward recreating those conditions.
| DEVELOPMENT OF BROADLY NEUTRALIZING ANTIBODIES IN HIV-1 INFECTED INDIVIDUALS
| The antibody response in HIV-1 infection
During acute HIV-1 infection, there is a vigorous immune response that is unable to contain virus replication or the establishment of latency. 37 In many cases, a single transmitted/founder virus establishes infection and then evolves within the host resulting in a diverse virus population. 38 The earliest changes to the virus population are driven by the CD8 + T-cell response that is induced as viremia increases 39 and places strong selection pressure on the virus, resulting in complete turnover of the virus pool within the first few weeks of infection. 40 The development of antibody responses follows a pattern, with antiviral antibodies being detected first as immune complexes 41 followed by free antibody directed at the HIV-1 envelope (Env) glycoprotein 41 (gp41) subunit, 41, 42 and then by the development of Env glycoprotein 120 (gp120)-binding antibodies. 41 These early antibody responses do not neutralize or place selective pressure on virus evolution 41 ; antibodies capable of neutralizing autologous viruses are not detectable until weeks to months after infection is established 19, 20 and have little to no activity against heterologous HIV-1 strains. 43 The initial gp41-directed antibody response is polyreactive and the antibodies are highly mutated, 42 and evidence indicates that at least some early responding B cells are primed prior to infection by non-HIV-1 antigens such as proteins contained in intestinal microbiota. 44 Acutely HIV-1-infected individuals do not make bnAbs, 41, 43 but during chronic HIV-1 infection, neutralization breadth develops to a greater or lesser degree in each person. [45] [46] [47] Breadth of plasma neutralizing activity develops incrementally, 48 and evidence suggests that protracted exposure to HIV-1 Env is required. [22] [23] [24] [47] [48] [49] [50] Neutralization breadth is not an all-or-nothing phenomenon-in one study, about half of a cohort of 205 chronically infected persons were capable of neutralizing about half of a panel of 219 hard-to-neutralize (tier 2) HIV-1 isolates. 45 When bnAbs arise, neutralization breadth is thought to be mediated by 1-2 specificities per individual, 51, 52 although serum mapping studies [53] [54] [55] [56] and algorithms designed to deconvolute neutralization data 57 suggest that in some individuals breadth may be mediated by three or more specificities of antibodies.
In addition, the acquisition of additional neutralization breadth can continue during ongoing HIV-1 infection. For example, in one infected individual (CH505), a CD4-binding site-directed bnAb developed 24 that was aided in its evolution by a cooperating antibody lineage also directed at the CD4 binding site but that did not initially have neutralization breadth. 23 During ongoing infection, this cooperating antibody lineage further evolved, developing bnAb activity. 22 The latter example suggests that the development of neutralization breadth is a dynamic process and that conditions favorable to the evolution of bnAbs may persist during chronic infection in some individuals. by the delayed antibody response in acute HIV-1 infection, 41 an increase in the proportion of activated memory B cells and exhausted B cells, non-specific plasmablast activation (leading to polyclonal immunoglobulin production), and a decline in the frequency of long-lived plasma cells. 42, [60] [61] [62] [63] In addition, Env-specific B cells are found in the activated and exhausted B-cell subsets in viremic individuals. 64 However, the B-cell dysfunction in HIV-1 infection does not prevent the generation of bnAbs, and the extent of dysregulation of circulating B-cell subsets during chronic infection shows no correlation with neutralization breadth. 65, 66 At this time, it is not known whether B-cell dysfunction is necessary for the development of breadth in HIV-1-infected individuals.
| Clinical characteristics of individuals making bnAbs
Longitudinal studies of HIV-1 infection have allowed researchers to map the development of bnAbs. [22] [23] [24] 26, 48 During acute/early HIV-1 infection, high viral load and an early decline in circulating CD4 + T cells were associated with the development of neutralization breadth, 48, 50 whereas individuals who had low or undetectable viral loads, such as long-term non-progressors, were found to have less neutralization breadth. 49 Time since infection also correlated with the development of breadth, 56 although whether this was due to the need for protracted Env exposure, persistent immune perturbation caused by HIV-1 infection, or both is not clear. although not all individuals taking antiretrovirals were completely suppressed. Thus, while prolonged Env exposure appears to be highly correlated with the development of neutralization breadth, there does appear to be a pathway to bnAb development in some individuals that lack prolonged or high-level Env exposure.
Common demographic characteristics do not appear to influence bnAb development. In a large longitudinal study of African HIV-1-infected individuals, there was no correlation between neutralization breadth and geographical origin, age, or gender, and no correlation with reported mode of transmission or risk factor. 50 In this same study, there was a correlation with subtype C infection and with the presence of human leukocyte antigen (HLA)-A*03, 50 although these two correlations were not observed in a different study. 47 In this second study, exome sequencing performed on matched sets of individuals with and without bnAbs did not reveal any specific gene that correlated with breadth, although some candidate variants were found. 47 To date, the data suggest that multiple factors contribute to the development of breadth in HIV-1-infected individuals.
| The association between autoimmunity and HIV-1 Infection
Early during the HIV-1 epidemic, clinicians noted that some HIV-1-infected individuals would go on to develop autoimmune phenomena, 75, 76 usually in the setting of uncontrolled infection. In addition, investigators noted that there was an underreporting of coincident HIV-1 infection and systemic lupus erythematosus (SLE), [77] [78] [79] [80] While there are bnAbs that do not react with human antigens, 83 most do. For some bnAbs where maturation has been studied from the initial B-cell rearrangement to breadth, development of breadth was correlated with acquisition of autoreactivity. 24 In one case, bnAb activity and autoreactivity were directly correlated, when a bnAb that also had reactivity with double stranded DNA was isolated from a person with coincident HIV-1 infection and SLE, 81 indicating that in that person, bnAb activity derived from an autoreactive B-cell pool.
In addition to autoreactivity, bnAbs usually have a high degree of somatic mutation and/or long heavy-chain complementarity determining region 3 (HCDR3) loops, 85 Thus, while it may not be necessary for a HIV-1 neutralizing antibody to exhibit characteristics of autoantibodies to have breadth, the two appear to be highly correlated. Because of this apparent correlation, we recently completed a study examining the relationship between autoantibodies and bnAb activity. 47 In two different cohorts, we found that HIV-1-infected persons making bnAbs were more likely to have serum autoantibodies as well as perturbations of their circulating T-cell populations, thus suggesting relaxed tolerance controls.
T-cell populations involved in regulation of B-cell responses and their relationship to bnAb induction are discussed in the following sections. 
| T FOLLICULAR HELPER CELLS
| T follicular helper cell differentiation
Tfh cell differentiation is a complex multi-step process that is influenced by numerous heterogeneous signals (reviewed in 112). The first step occurs when naive CD4 + T cells are primed by dendritic cells (DCs)
in LNs: an initial Tfh-lineage fate decision is made during the first few rounds of cell division. 113 Factors that influence CD4 + cell Tfh-lineage differentiation include the cytokine environment, ICOS ligation, and signaling via the T-cell receptor (TCR). In mice, IL-6 plays an important role in promoting Tfh cell generation and induces upregulation of the transcription factor B-cell lymphoma 6 (Bcl6), which is a central regulator of Tfh differentiation. [114] [115] [116] However, although there is evidence that IL-6 can also promote Tfh differentiation in humans, 117 it is a not a good inducer of Bcl6 expression in human CD4 + T cells. Tfh cell differentiation also requires ligation of ICOS by its ligand ICOSL. 126 and IL-21 production in vitro, contributing to their poor helper capacity. 190 The functional capacity of circulating Tfh cells was also found to be impaired: the proportion of cells producing cytokines including IL-21 was reduced, and they again exhibited a reduced B-cell helper capacity in vitro. 163 These defects in Tfh cell function appear to develop very rapidly, during the acute phase of HIV-1 infection. 190, 197 Analysis of both GC Tfh cells in SIV-infected macaques 198 
| Circulating Tfh populations
| Relationship between Tfh cells and bnAb induction in HIV-1 infection
As the majority of bnAbs show evidence of extensive somatic hy- 
| REGULATORY CELL POPULATIONS AND THEIR RELATIONSHIP TO BNAB INDUCTION
| Regulation of GC responses
GC responses need to be precisely controlled to enable generation of high-affinity antibodies and prevent the production of autoantibodies and development of autoimmune disease and chronic inflammation is spontaneous B-cell activation, GC formation, and autoantibody production, and the animals develop a lupus-like phenotype. 212, 213 Likewise increased numbers of circulating CXCR5 + CD4 + T cells, frequencies of which correlate with autoantibody titers, are observed in patients with SLE and other autoimmune diseases including Sjogren's syndrome and myasthenia gravis.
162,214
As discussed above, Tfh cell differentiation is a multi-step process 47 As discussed above, autoantibodies were also detected in a higher proportion of the group of subjects who produced bnAbs than those who did not. Together, these findings suggest that bnAb development during HIV-1 infection may be favored by a relaxation in regulatory CD4 + T-cell control of antibody production that enables a strong GC response and permits some degree of autoreactive antibody production. 47 
| IMPLICATIONS FOR DESIGN OF BNAB-INDUCING VACCINES
A major focus of efforts to develop bnAb-inducing vaccines has been on antigen design. [287] [288] [289] Vaccine development efforts are, thus, likely to benefit from consideration of these three inter-related factors. First, a strong antigenspecific CD4 + Tfh cell response needs to be elicited. As discussed above, it is currently unclear whether this should ideally target particular CD4 + epitopes within the vaccine antigen, although it can be speculated that targeting of high-affinity epitopes in close proximity to bnAb epitopes may be beneficial. However, the use of immunization 294 although this type of approach will need to be carefully safety-tested in animal models prior to study in human trials.
In summary, study of the mechanisms that enable bnAb induction in some HIV-infected individuals has given important insight into how bnAb induction may be achieved by vaccination. The benefit to rational vaccine design strategies is such that achievement of bnAb induction by vaccination now seems very likely. 
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